Efficacy and safety of sunitinib on metastatic renal cell carcinoma: a single-institution experience.
about
Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis.Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart reviewImpact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countriesCurrent status of targeted therapy for advanced renal cell carcinomaDecreased efficacy of drugs targeting the vascular endothelial growth factor pathway by the epigenetic silencing of FLT1 in renal cancer cells.Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study.Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients.Management of sunitinib adverse events in renal cell carcinoma patients: the Asian experience.Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain.Validation of the MSKCC and Heng risk criteria models for predicting survival in patients with metastatic renal cell carcinoma treated with sunitinib.Clinical outcomes of the sequential use of pazopanib followed by everolimus for the treatment of metastatic renal cell carcinoma: a multicenter study in Korea.
P2860
Q33437427-D6BEAB3C-26E3-4887-BE90-A7D93C0DDBD8Q34657590-9EE828F8-D705-47BF-B602-75091D02953EQ34982554-AB0D9B0B-9FA8-44A5-976E-CC07BEB748F8Q35903850-76B20A25-8C1E-4005-AC19-5BC90FCFDAA6Q36067203-663DD813-9B1F-423A-8C10-0A0D7FC404FCQ37387563-3FF79913-FEAD-4FA4-A82D-4C5255F7691BQ37650644-BA1E8BFF-0EF3-4AEB-88D9-41B2F86076B5Q38004605-A6BB1A3C-2F78-432A-8F1C-F25D64BD317CQ38091137-392C661C-9A7A-41CE-A04F-2BDD1BFEB598Q45082802-17348006-AC59-4BEA-8C6C-BB0362D53505Q47417154-9435CF62-8184-4FF5-A71F-CA6D70D16FC0
P2860
Efficacy and safety of sunitinib on metastatic renal cell carcinoma: a single-institution experience.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Efficacy and safety of sunitin ...... single-institution experience.
@ast
Efficacy and safety of sunitin ...... single-institution experience.
@en
Efficacy and safety of sunitin ...... single-institution experience.
@nl
type
label
Efficacy and safety of sunitin ...... single-institution experience.
@ast
Efficacy and safety of sunitin ...... single-institution experience.
@en
Efficacy and safety of sunitin ...... single-institution experience.
@nl
prefLabel
Efficacy and safety of sunitin ...... single-institution experience.
@ast
Efficacy and safety of sunitin ...... single-institution experience.
@en
Efficacy and safety of sunitin ...... single-institution experience.
@nl
P2093
P2860
P1476
Efficacy and safety of sunitin ...... single-institution experience
@en
P2093
Chong Koo Sul
Eugene Hwang
Jae Sung Lim
P2860
P304
P356
10.4111/KJU.2010.51.7.450
P50
P577
2010-07-20T00:00:00Z